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Abstract
Activation of the innate immune system is commonly associated with depression. Immunomodulatory drugs may have
efficacy for depressive symptoms that are co-morbidly associated with inflammatory disorders. We report a large-scale re-
analysis by standardized procedures (mega-analysis) of patient-level data combined from 18 randomized clinical trials
conducted by Janssen or GlaxoSmithKline for one of nine disorders (N= 10,743 participants). Core depressive symptoms
(low mood, anhedonia) were measured by the Short Form Survey (SF-36) or the Hospital Anxiety and Depression Scale
(HADS), and participants were stratified into high (N= 1921) versus low-depressive strata based on baseline ratings. Placebo-
controlled change from baseline after 4–16 weeks of treatment was estimated by the standardized mean difference (SMD)
over all trials and for each subgroup of trials targeting one of 7 mechanisms (IL-6, TNF-α, IL-12/23, CD20, COX2, BLγS,
p38/MAPK14). Patients in the high depressive stratum showed modest but significant effects on core depressive symptoms
(SMD= 0.29, 95% CI [0.12–0.45]) and related SF-36 measures of mental health and vitality. Anti-IL-6 antibodies (SMD=
0.8, 95% CI [0.20–1.41]) and an anti-IL-12/23 antibody (SMD= 0.48, 95% CI [0.26–0.70]) had larger effects on depressive
symptoms than other drug classes. Adjustments for physical health outcome marginally attenuated the average treatment
effect on depressive symptoms (SMD= 0.20, 95% CI: 0.06–0.35), but more strongly attenuated effects on mental health and
vitality. Effects of anti-IL-12/23 remained significant and anti-IL-6 antibodies became a trend after controlling for physical
response to treatment. Novel immune-therapeutics can produce antidepressant effects in depressed patients with primary
inflammatory disorders that are not entirely explained by treatment-related changes in physical health.
Introduction
Activation of the innate immune system is associated with
major depressive disorder (MDD). Case-control studies and
meta-analyses have reported that patients have modestly
elevated peripheral blood levels of pro-inflammatory cyto-
kines and acute phase proteins, including C-reactive protein
(CRP) [1, 2], tumor necrosis factor-alpha (TNF-α) [3–5],
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and interleukin-6 (IL-6) [4, 6]. Increased cerebrospinal fluid
levels of pro-inflammatory cytokines have been reported
[7, 8] and correlated with reduced hippocampal volume in
depressed patients [9]. A central pro-inflammatory process
has also been indicated by post mortem studies of micro-
glial activation and PET studies of TSPO ligand binding in
MDD [10, 11].
Clinical evidence for a causal effect of inflammatory chal-
lenge on the pathogenesis of depressive symptoms includes
data from interferon alpha (IFN-α) treatment trials for hepatitis
C, which frequently induces symptoms of depression and fati-
gue, with a concomitant increase in inflammatory markers in
peripheral blood [12] and CSF [13]. In the chronic social defeat
stress model in rodents, animals susceptible to developing
persistent depression-like behaviors manifest higher peripheral
blood levels of IL-6 both before and after stress exposure [14].
Susceptibility to developing depressive phenotypes was
reduced in IL-6−/− animals; but increased in wild type animals
by transplanting the immune cells of donor animals that had
previously expressed a depressive response to social stress [14].
To date, only a few studies have addressed the therapeutic
hypothesis that anti-inflammatory drugs may have anti-
depressant efficacy. Infliximab, an anti-TNF-α antibody, was
not effective for depressive symptoms in subjects with
treatment-resistant MDD; but post hoc analysis indicated that
the subgroup of patients with high CRP was more responsive
[15]. A small molecule inhibitor of P38 MAP kinase was not
consistently effective in two studies of MDD [16]. However,
there was evidence of a moderate-sized anti-inflammatory
drug effect (SMD= 0.34; 95% CI [0.11–0.57]) on depressive
symptoms in a meta-analysis of clinical trial data on NSAIDs
and anti-cytokine antibodies in patients with a primary diag-
nosis of depression or inflammatory disorder [17], and in a
meta-analysis of anti-cytokine antibody effects on depressive
symptoms in inflammatory disorders (SMD= 0.44; 95% CI
[0.22–0.59]) [4, 18–21].
In any analysis of depressive symptom changes during
anti-inflammatory drug treatment of an inflammatory dis-
order it is important to control for treatment effects on
physical symptoms (e.g., swollen and painful joints in
rheumatoid arthritis). Anti-inflammatory drug effects on
psychological symptoms may arise secondarily to treatment
effects on the physical signs and symptoms of inflammatory
disorders. Alternatively, the antidepressant efficacy of anti-
inflammatory drugs may reflect a direct, mechanistically
related effect of treatment. This hypothetical dilemma
remains unresolved [17, 18].
Here we report a large, integrated analysis of existing clinical
trial datasets to further investigate anti-inflammatory drug
effects on depressive symptoms. Access to patient-level data
(N= 10,743) enabled us to identify the cohort of trial partici-
pants with high depressive symptoms at baseline, to focus on
improvement in the DSM 5 cardinal depressive symptoms of
depressed mood and anhedonia, and to control for physical
health outcomes (although high depressive patients were not
randomly allocated to treatment groups in the primary studies).
We analyzed 18 double-blind, placebo-controlled, randomized
clinical trials, sponsored by Janssen or GlaxoSmithKline, of 9
compounds targeting 7 mechanisms of action (TNF-α, IL-12/
23, IL-6, CD20, COX2, BLγS, and P38/MAPK14) in patients
with a primary diagnosis of one of 9 inflammatory or oncolo-
gical disorders (see Table 1).
Methods
Study inclusion criteria
Placebo-controlled, double-blind, randomized, parallel
group studies, with publically pre-registered designs, were
included if (1) the drug primarily targeted an immune
mechanism of action and (2) depressive symptom severity
was assessed at baseline and follow-up visits scheduled
4–16 weeks post-randomization; see Table 1 and Supple-
mentary Table 1 for details.
Outcome measures
For all but one trial, the SF-36 Health Survey (version 1.0 or
2.0) [22] was used as a patient reported outcome (PRO)
measure. The SF-36 comprises 36 self-report measures of
physical and mental health that can be summarized by 8
domain scores and two component scores (physical and
mental health). We used the mental health component score
and the vitality domain score as standard SF-36 outcomes.
Additionally, to focus on depressive symptoms, we con-
structed a depressive symptom summary score (range,
0–100). This was based on the two SF-36 questions (“Have
you felt downhearted and depressed?” and “Have you felt so
down in the dumps that nothing could cheer you up?”) that
most closely corresponded to core DSM-5 symptoms of
depressed mood and anhedonia; see Supplementary Informa-
tion. In one study (C0743T09), the Hospital Anxiety and
Depression Scale (HADS [23]) was used instead of the SF-36.
In an independent study where both scales were measured, the
HADS-D was significantly correlated with the defined SF-36
depressive symptom score (Spearman r= 0.63, p < 0.0001).
Depressive symptom stratification
Patients were stratified as belonging to high depressive or
low depressive subgroups based on their scores on the two
SF-36 questions related to depressed mood and anhedonia.
A patient was assigned to the high depressive stratum if they
rated at least one of these two key symptoms as present at
least “most of the time” in the previous 4 weeks and rated the
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other symptom as present at least “some of the time”; Sup-
plementary Fig. 1. In C0743T09, patients were classified as
high depressive if baseline total HADS score was ≥8 [23].
Notably patients with high depressive symptoms were not
randomly allocated to treatment in any of the studies (Sup-
plementary Table 2), which fundamentally constrains causal
interpretation of treatment effects on this subgroup of patients.
Analysis of baseline data and treatment effects
Treatment effects were estimated using mixed-effect linear
models with repeated measures (MMRM). MMRMs were
chosen for their ability to leverage all available data and to
minimize the introduction of biases in the context of
missing data under the assumption of missing at random
[24]. The extent of missing data for each study, due to
participant withdrawal, is indicated in Table 1 by the dif-
ference between N at baseline and follow-up assessments.
Separate models were fit for patients in high and low
depressive symptom strata. Depressive symptom score was
the primary dependent variable. Treatment, time, and
treatment-by-time interaction were fixed effects with time
modeled as a repeated measure. Participants were treated
as random effects in the model. For multi-country studies
with >35 patients per treatment arm (Table 1), country was
included as a covariate. The association of baseline bio-
markers with treatment response is shown in Supplemen-
tary Table 3. The effects on antidepressant treatment
outcomes of age, body mass index (BMI), sex and corti-
costeroid use were not consistently significant across stu-
dies; see Supplementary Table 2 and Supplementary
Fig. 2.
The within-treatment change was estimated by contrast-
ing the least square means of depressive symptom score at
baseline and first follow-up visits. The drug treatment effect
was estimated by contrasting the symptom change in the
drug treated arm versus the placebo arm. Analyses were
performed using SAS 9.2 and 9.4 (www.sas.com), and R
3.3.0. The statistical framework is described in more detail
for the illustrative example of a phase 2 trial of sirukumab
for RA, C1377T04 (Supplementary Fig. 3).
Adjustment for treatment effects on physical health
We controlled the estimation of treatment effects on mental
health for the effects of treatment on physical health in two
ways: (i) for each study, the severity scale used to measure
clinical efficacy for primary disease signs and symptoms
(e.g., DAS28-CRP in a rheumatoid arthritis trial C1377T04)
was added to the mixed model as a time-dependent fixed
effect; (ii) for a subset of 12 studies (delineated in Table 1)
that had specified a responder/non-responder criterion a
priori, we estimated the treatment effect on depressive
symptoms only in those high depressive patients who were
defined as non-responders on the primary (physical health)
endpoint of the trial.
Mega-analysis
For each study, the standardized mean difference (SMD)
was estimated by Cohen’s d: the difference in least square
means between the treatment and placebo arms divided by
the pooled standard deviation. This unit-less measure can be
compared and combined across studies [17]. The R package
metafor was used for analysis and visualization of forest
plots. Treatment effects are reported primarily in terms of
95% confidence intervals on the mean SMD; if the 95% CI
does not include zero, the treatment effect is statistically
significant with two-tailed P < 0.05. Heterogeneity across




The clinical trials included are listed in Table 1. Active
treatment groups were defined as patients receiving the new
immunomodulatory drug at any dose. Treatment and pla-
cebo groups may have received concomitant medication as
detailed in Supplementary Table 1.
For each study we used self-reported measures of mood
and anhedonia at baseline to stratify patients into two sub-
groups, designated as high or low depressive. The proportion
of patients belonging to the high depressive stratum varied
between studies categorized by primary disorder (Table 1;
Fig. 1a), with the greatest proportion of high depressive
patients in studies of rheumatoid arthritis (P= 0.004, 2-tailed
t-test, rheumatoid arthritis vs. all other disorders). Baseline
CRP was measured in most studies and the mean baseline
CRP (averaged across all patients in each study) correlated
positively with the proportion of high depressive patients
(Pearson R2= 0.32, P= 0.04, Fig. 1b).
Treatment and placebo effects on core depressive
symptoms
In the high depressive stratum of patients (N= 1921 over all
18 studies), we estimated the change from baseline in
depressive symptom severity in each treatment arm (active
drug or placebo) in each study. Active drug treatment was
always associated with significant improvement in depres-
sive symptoms. However, in most (17) studies there was
also significant improvement in depressive symptoms after
treatment with placebo plus allowed concomitant
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medication. The placebo effect size varied widely between
studies (Supplementary Fig. 4), possibly reflecting the het-
erogeneity of trial designs with respect to the control of
concomitant drugs, like methotrexate or corticosteroids, that
are known to affect mood states, or differences in disease
states and study populations.
Over all 18 trials, there was a modest but significant
antidepressant effect of immunological treatments compared
to placebo (SMD= 0.29; 95% CI [0.12,0.45]) (Fig. 2a).
To explore the significant heterogeneity of effect sizes
related to mechanistic differences between drugs, we
computed placebo-controlled treatment effects on change
from baseline depressive symptom scores for each of 7
clusters or classes of studies targeting the same mechanism
of action: 5 studies targeted TNFα (3, infliximab; 2,
golimumab); 3 targeted BLγS (belimumab); and 2 targeted
IL-6 (1, sirukumab; 1, siltuximab) IL-12/23 (ustekinu-
mab), CD20 (ofatumumab), P38/MAPK (losmapimod), or
COX-2 (GW406381). The anti-IL-12/23 antibody
demonstrated significant improvement in depressive
symptoms compared to placebo (SMD= 0.48; 95% CI
[0.26, 0.70]). Studies of the two anti-IL-6 antibodies also
demonstrated significant antidepressant efficacy vs. pla-
cebo (SMD= 0.80; 95% CI [0.20, 1.41]). There were non-
significant trends in favor of improved depressive symp-
toms in patients treated with the anti-BLγS antibody
(SMD= 0.34; 95%CI [−0.07, 0.76]), and the two anti-
TNFα antibodies (SMD= 0.30; 95% CI [−0.08, 0.67]).
Studies of the small molecule COX-2 inhibitor
(GW406381) demonstrated a non-significant trend in favor
of improved depressive symptoms in patients treated with
placebo (SMD=−0.12, 95% CI [−0.34, 0.10]), but it was
notable that the change in the placebo arm of this study
appeared unusually large (Supplementary Fig. 4).
Controlling for treatment effects on physical health
outcomes
First, we included the continuous measure of physical sign
and symptom severity measured for each study as a cov-
ariate in the model used to estimate treatment effects on
depressive symptoms (Table 1). After this statistical
adjustment, antidepressant effects were somewhat atte-
nuated, but the primary mega-analytic estimate of effect size
over all studies remained significantly different from zero
(SMD= 0.20; 95% CI [0.06, 0.35]). The antidepressant
effect of ustekinumab (targeting IL-12/23) remained sig-
nificant after correction for physical sign and symptom
changes (SMD= 0.40; 95% CI [0.18, 0.62]); whereas the
antidepressant effect of drugs targeting IL-6 was attenuated
to a non-significant trend (Fig. 2b).
Second, using data from 7 Janssen and 5 GSK studies for
which a prior decision rule could be used to dichotomize
patients as “responders” or “non-responders” with respect to
the primary (physical health) endpoint of each trial, we
estimated treatment effects on depressive symptoms in the
non-responder subgroups alone. The overall antidepressant
effect remained significant (SMD= 0.38 95% CI [0.21,
0.55]), with significant effects on depressive symptom
severity found in non-responders to treatment with anti-
TNF-α (SMD= 0.35; 95% CI [0.09–0.60]) and anti-IL-6
(SMD= 0.88; 95% CI [0.16–1.59]) antibodies (Fig. 2c).
Effects of treatment on the SF-36 Mental health
component score and the vitality domain score
There was a significant effect of anti-inflammatory
drug treatment over the 17 studies reporting the SF-36 for
both the mental health component score (SMD= 0.28; 95%
Fig. 1 High depressive symptoms in clinical trial participants at
baseline. a Left panel, percentage of patients meeting criteria for high
depressive symptoms at baseline for each trial, grouped by the primary
disease treated in the study. Abbreviations: rheumatoid arthritis (RA),
multicentric Castleman’s disease (MCD). Right panel, boxplot indi-
cating significantly higher percentage of patients with high depressive
symptoms in RA studies compared with other studies combined. The
box and whiskers plot indicates median value, interquartile range and
extreme values. b Scatterplot of percentage of patients with high
depressive symptom scores at baseline vs. mean baseline C-reactive
protein (CRP). Each point corresponds to a study
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CI [0.11, 0.44]) and the vitality domain score (SMD= 0.24;
95% CI [0.09, 0.39]). However, treatment effects on the
mental health component score were reduced (SMD= 0.14;
95% CI [0.02, 0.27]), and the vitality domain score was
attenuated to a non-significant trend, by statistical control
for treatment effects on physical health (Figs. 3 and 4).
Fig. 2 Effects of immunomodulatory drugs (overall and classified by
mechanism of action) on depressive symptoms in high depressive
stratum of patients. a Change in depressive symptom scores from
baseline to follow-up visit was compared between active treatment and
placebo arms. The standardized mean difference (SMD) is a measure
of placebo-controlled antidepressant effect size that can be compared
and combined across studies. b Immunomodulatory drug effects on
depressive symptoms were estimated by a linear model including the
primary disease symptom scale appropriate for each study (Table 1) as
a covariate to control for drug effects on physical health outcome.
c Immunomodulatory drug effects on depressive symptoms were
estimated only in the subgroup of high depressive patients who did not
respond physically to drug treatment (non-responders)
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Sensitivity Analyses
There was no significant treatment effect of anti-
inflammatory drugs on the depressive symptom severity
score, the mental health component score, or the vitality
domain score, in parallel analyses of SF-36 data including
all subjects, rather than just those with high depressive
symptoms (In 18 trials; depressive symptom score: SMD=
0.00; 95% CI [−0.05, 0.06], see Supplementary Figs. 5–7).
Additional sensitivity analyses were included to assess
the effects of the additional covariates of age, gender,
and corticosteroid use (Supplementary Fig. 8 and
Supplementary Table 2), and the stringency of the definition
for the high depressive symptom cohort (Supplementary
Fig. 2). The effects on the SF-36 anhedonia and depression
items were evaluated separately, and the effect of treatment
on depressive symptoms among primary disease responders
is shown (Supplementary Fig. 2).
Discussion
Our principal findings are that depressive symptoms are
frequent among patients recruited to clinical trials for non-
Fig. 3 Effects of
immunomodulatory drugs
(overall and classified by
mechanism of action) on SF-36
Mental Health Component (MC)
scores in the high depressive
stratum of patients. a Change in
SF-36 MC scores from baseline
to follow-up visit was compared
between active treatment and
placebo arms. The standardized
mean difference (SMD) is a
measure of placebo-controlled
antidepressant effect size that
can be compared and combined
across studies. b
Immunomodulatory drug effects
on SF-36 MC scores were
estimated by a linear model
including the primary disease
symptom scale appropriate for
each study (Table 1) as a
covariate to control for drug
effects on physical health
outcome
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psychiatric inflammatory disorders and that immunomodu-
latory drug treatment generally causes a modest, but sig-
nificant, improvement in depressive symptoms, specifically
in the subgroups of patients with high depressive symptoms
at baseline (SMD= 0.29; 95% CI. 0.12–0.45). These results
are compatible with prior data implicating inflammation in
the pathophysiology and response to treatment of depres-
sion [1, 2, 25, 26]. This modest effect size is comparable to
meta-analytic estimates of antidepressant efficacy of selec-
tive serotonin reuptake inhibitors in patients with major
depressive disorder [27], and comparable to the standar-
dized effect sizes seen in meta-analyses of inflammatory
cytokines in case-control cohorts [1, 4, 6, 28].
In evaluating these results, it is reasonable to ask how
much of the improvement in mental health is attributable to
treatment benefits for the primary disease states evaluated in
these trials. When we controlled statistically for treatment
effects on physical health, the mega-analytic estimate of
antidepressant effect size was reduced (SMD= 0.20; 95%
CI, 0.06–0.35) but remained significant. Likewise, anti-IL-6
and anti-TNF antibodies had significant beneficial effects on
core depressive symptoms, even in patients who had not
responded to treatment in terms of improved physical health
for the primary disease states studied. In contrast, broader
measures of mental health or vitality, which included
questions probing somatic symptoms, such as fatigue, were
Fig. 4 Effects of
immunomodulatory drugs
(overall and classified by
mechanism of action) on SF-36
Vitality Domain scores in the
high depressive stratum of
patients. a Change in SF-36
vitality domain scores from
baseline to follow-up visit was
compared between active
treatment and placebo arms. The
standardized mean difference
(SMD) is a measure of placebo-
controlled antidepressant effect
size that can be compared and
combined across studies.
b Immunomodulatory drug
effects on SF-36 vitality domain
scores were estimated by a linear
model including the primary
disease symptom scale
appropriate for each study
(Table 1) as a covariate to
control for drug effects on
physical health outcome
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less robust to statistical correction for physical health out-
comes. We conclude that the effects of anti-inflammatory
drugs on depressive symptoms are not entirely attributable
to their effects on physical health. However, it may be that
somatic symptoms (e.g., fatigue) are more strongly coupled
to peripheral tissue disease activity than psychological
symptoms (e.g., anhedonia). Nevertheless, it is noteworthy
that conventional assessments of primary disease severity
sometimes included a biomarker index of inflammation
(e.g., the DAS28-CRP index used to assess rheumatoid
arthritis severity includes CRP). Adjusting antidepressant
effects of treatment by DAS28-CRP scores may correct for
not only physical health effects of treatment but may also
attenuate the effect size of any treatment on depressive
symptoms or fatigue that are mediated by inflammatory
mechanisms.
The antidepressant effect size varied between different
classes of drug target. Antibodies targeting IL-6 or IL-12
and IL-23 (IL-12/23) had large and statistically significant
effect sizes on core depressive symptoms before correction
for physical health outcomes. Moreover, the antidepressant
effect of ustekinumab (anti-IL-12/23 antibody) remained
significant after correction for physical health outcome, and
the effect of sirukumab and siltuximab (anti-IL-6 anti-
bodies) remained significant in non-responders for the pri-
mary disease states evaluated. A variety of evidence
implicates IL-6 in the pathogenesis of depression
[9, 29, 30], and a phase 2 trial of sirukumab for patients
with MDD and CRP >3 mg/L has recently completed
(clinicaltrials.gov ID: NCT02473289). Increased levels of
IL-12 in depressed patients were reduced by mono-
aminergic antidepressant treatment [31, 32]. Antibodies
targeting BLγS and TNF-α also demonstrated trend-level
efficacy for depressive symptoms. Small molecules target-
ing P38MAPK or COX2 demonstrated the least anti-
depressant effect which is compatible with the lack of
compelling evidence for antidepressant efficacy of these
mechanisms in previously published MDD trials [16].
The main strength of this study is that we have reported
depressive symptom outcomes in 1921 patients treated with
one of a range of mechanistically selective and innovative
drugs in randomized clinical trials. Access to patient-level
data enabled post hoc patient stratification and statistical
controls for physical health outcomes, which is not possible
in literature-based meta-analyses. The main limitations are
related to the fact that the primary studies were not pro-
spectively designed to test drug effects on depressive or
other psychological states. For example, depressive symp-
toms were usually assessed by the SF-36 questionnaire.
This PRO measure has the merit of being widely used,
allowing consistent evaluation of treatment effects across a
large number of studies and participants; however, it was
not intended to serve as an endpoint for antidepressant
efficacy. It is noteworthy, nonetheless, that the depressive
symptom score derived from the SF-36 is significantly
correlated with HADS-D scores. Similarly, the vitality
domain score of the SF-36 includes questions related to
fatigue but it is not designed to test efficacy of anti-
inflammatory drugs in treating symptoms of fatigue.
A related issue is that the studies were focused on a
diverse range of primary disorders. The comparisons
between different anti-inflammatory drug effects on
depression were not controlled by design for type or
severity of physical comorbidity, although we endeavored
to mitigate this issue by including physical health measures
as covariates in the analysis of depressive symptom scores.
The primary studies also varied in terms of the “standard of
care” provided to patients in both placebo and active
treatment groups. In particular, studies differed in terms of
allowed concomitant medications and the percentage of
patients using corticosteroids. In each study, however,
patients in both the placebo and active treatment groups
were subject to the same standard of care, so this potential
between-study difference appeared unlikely to bias within-
study estimation of treatment effects; furthermore, a post
hoc analysis found no significant effect of corticosteroid use
on between-study variation in treatment effect size (Sup-
plementary Table 2). Likewise, in each study, patients were
well-matched for age, sex, and BMI between treatment
groups, suggesting that these factors are unlikely to bias
estimation of within-study antidepressant effects. We fur-
ther evaluated the effect of between-study variability in age,
sex, and BMI and found only a small age effect indicating
that older subjects are less responsive (Supplementary
Fig. 2). We were unable to rigorously assess dose-response
relationships, because most studies used more than one dose
of active treatment, but not always the same dose range in
different studies of the same drug, and data on dose/occu-
pancy relationships were not available for all drugs. Finally,
patients with high depressive symptoms were not randomly
allocated to treatment in any of the studies, which funda-
mentally constrains causal interpretation of treatment effects
in this subgroup of treated patients.
Collectively the limitations of our study highlight the
need for future studies designed primarily to evaluate the
effects of anti-inflammatory drugs on validated efficacy
endpoints for depression and fatigue. Future studies also are
needed to explore whether inflammatory biomarkers at
baseline can identify subgroups of MDD patients likely to
benefit from anti-inflammatory drug treatment. Greater use
of predictive biomarkers may also be important in managing
safety risks by precluding treatment of patients unlikely to
respond, We note that antidepressants include a black box
warning indicating they may increase the risk of suicidal
thinking in children and adolescents, and that recently the
IL-17 inhibitor brodalumab was approved as a treatment for
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psoriasis with a warning that it has been linked to suicidal
ideation [32]. In future trials of immunomodulatory drugs
for inflammatory disorders associated with high levels of
mental health comorbidity, such as rheumatoid arthritis, it
would be useful to measure outcomes early and frequently
to test whether direct effects of treatment on mental health
can be demonstrated before treatment effects on physical
health are evident.
We conclude that anti-inflammatory drugs can have
therapeutic effects on psychological symptoms of depres-
sion associated with inflammatory disease that are not
entirely attributable to treatment effects on physical health.
Further studies are required to confirm these findings
directly.
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